Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma

被引：3
|
作者：
Gorphe, Philippe [1 ]
Chekkoury Idrissi, Younes [1 ]
Tao, Yungan [2 ]
Moya-Plana, Antoine [1 ]
Casiraghi, Odile [3 ]
Janot, Francois [1 ]
Blanchard, Pierre [2 ]
Mirghani, Haitham [1 ]
Temam, Stephane [1 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Head & Neck Oncol, Villejuif, France
[2] Univ Paris Saclay, Inst Gustave Roussy, Dept Radiotherapy, Villejuif, France
[3] Univ Paris Saclay, Inst Gustave Roussy, Dept Pathol, Villejuif, France
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2019年 / 41卷 / 04期
关键词：
human papillomavirus; N3; oropharyngeal neoplasms; p16; immunohistochemistry; smoking history; POSITIVE HEAD; CANCER; OUTCOMES; CHEMORADIOTHERAPY; RISK; RADIOTHERAPY; INTEGRATION; PROGNOSIS; RADIATION; SURVIVAL;
D O I：
10.1002/hed.25523
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Background We investigated the survival of patients with a p16-positive N3 oropharyngeal squamous cell carcinoma (OPSCC) and the prognostic significance of patient, tumor, and treatment characteristics. Methods We retrospectively reviewed the data of patients treated at our Cancer Center for a p16-positive N3 OPSCC between 2003 and 2016. End points were overall survival (OS) and progression-free survival (PFS). Results A total of 29 patients were included. The 5-year OS and PFS were 67.5% and 59.1%, respectively. Smoking history above 10 pack-years and the absence of human papillomavirus DNA were associated with worse OS (P = .02 and P = .03, respectively) and PFS (P = .02 and P = .02, respectively). Induction chemotherapy or radical neck dissection were not associated with different treatment outcomes. Conclusion Patients with an N3 p16-positive oropharyngeal cancer in our series had a 5-year OS rate of 67.5%. Smoking history and viral DNA were prognostic factors associated with survival.
引用
收藏
页码：1039 / 1045
页数：7
相关论文
共 50 条
  • [1] Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS
    Carey, Ryan M.
    Brody, Robert M.
    Shimunov, David
    Shinn, Justin R.
    Mady, Leila J.
    Rajasekaran, Karthik
    Cannady, Steven B.
    Lin, Alexander
    Lukens, John N.
    Bauml, Joshua M.
    Cohen, Roger B.
    Basu, Devraj
    O'Malley, Bert W., Jr.
    Weinstein, Gregory S.
    Newman, Jason G.
    LARYNGOSCOPE, 2021, 131 (12) : E2865 - E2873
  • [2] Orbital mass as first presentation of metastatic p16-positive oropharyngeal squamous cell carcinoma
    Corbett, J.
    Wilke, D.
    Trites, J.
    Lamond, N.
    CURRENT ONCOLOGY, 2017, 24 (06) : E551 - E554
  • [3] The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma
    Skillington, S. Andrew
    Kallogjeri, Dorina
    Lewis, James S., Jr.
    Piccirillo, Jay F.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2017, 143 (03) : 253 - 259
  • [4] A case report of thyroid metastasis from p16-positive oropharyngeal squamous cell carcinoma
    Takenobu, Masao
    Moritani, Sueyoshi
    Yoshioka, Kana
    Morisaki, Tsuyoshi
    Kitano, Hiroya
    ENDOCRINE JOURNAL, 2018, 65 (04) : 479 - 483
  • [5] Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease
    Zenga, Joseph
    Haughey, Bruce H.
    Jackson, Ryan S.
    Adkins, Douglas R.
    Aranake-Chrisinger, John
    Bhatt, Neel
    Gay, Hiram A.
    Kallogjeri, Dorina
    Martin, Eliot J.
    Moore, Eric J.
    Paniello, Randal C.
    Rich, Jason T.
    Thorstad, Wade L.
    Nussenbaum, Brian
    LARYNGOSCOPE, 2017, 127 (09) : 2033 - 2037
  • [6] Asymptomatic p16-Positive Oropharyngeal Squamous Cell Carcinoma An Emerging Trend
    Sand, Jordan P.
    Haughey, Bruce H.
    Nussenbaum, Brian
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2014, 140 (10) : 975 - 977
  • [7] Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis
    Sedghizadeh, Parish P.
    Billington, William D.
    Paxton, Dain
    Ebeed, Rabeh
    Mahabady, Susan
    Clark, Glenn T.
    Enciso, Reyes
    ORAL ONCOLOGY, 2016, 54 : 15 - 27
  • [8] Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease
    Bhattasali, Onita
    Han, Jeannie
    Thompson, Lester D. R.
    Buchschacher, Gary L., Jr.
    Abdalla, Iman A.
    Iganej, Shawn
    ORAL ONCOLOGY, 2018, 78 : 151 - 155
  • [9] Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: A critical analysis of patterns and outcomes
    Sinha, P.
    Thorstad, W. T.
    Nussenbaum, B.
    Haughey, B. H.
    Adkins, D. R.
    Kallogjeri, D.
    Lewis, J. S., Jr.
    ORAL ONCOLOGY, 2014, 50 (01) : 45 - 51
  • [10] Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing
    Nauta, I. H.
    Rietbergen, M. M.
    van Bokhoven, A. A. J. D.
    Bloemena, E.
    Lissenberg-Witte, B., I
    Heideman, D. A. M.
    de Jong, R. J. Baatenburg
    Brakenhoff, R. H.
    Leemans, C. R.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1273 - 1279
12345